Small Biotechs Push Radiopharmaceutical Programs Toward Licensing and Conference Stage
Sourced from 7 publications
- •Perspective Therapeutics will present updated VMT-α-NET program data at the 38th EORTC-NCI-AACR Symposium 2026.
- •Molecular Targeting Technologies Inc. is seeking licensing and co-development partners for its EvaThera radiopharmaceutical platform.
- •Both announcements are early-stage corporate milestones rather than clinical breakthroughs or completed transactions.
- •Continued activity from small biotechs reflects sustained interest in radiopharmaceuticals as a growing therapeutic category.
Sources
Novartis bust highlights ongoing challenges with CVOTs
bioworld
West Chester Biotech Targets Radiopharma Partnerships
mychesco
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation...
financialcontent
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation...
nynewscast
Inside the deal: How a Montco biotech secured a Pfizer drug candidate
Bizjournals
Biotechnology at scale: Europe’s next competitiveness test
Politico EU
Frost & Sullivan Released the 2026 Global Stem Cell Industry Development Blue Bo...
thewesterlysun
Curated from 7 sources. Every summary is reviewed for accuracy, but may still contain errors. We always link to original sources for verification.
Related Stories
About Meridian
Meridian is a free daily newsletter delivering signal-scored news stories with forward-looking analysis every morning. Stories are scored across six criteria (global leverage, capital impact, temporal durability, career relevance, decision utility, and narrative clarity) then assigned to Big Signal, Core, or Quick tiers.
Get Meridian in your inbox
The stories that matter, every morning at 06:00.